TLX1 is a homeodomain transcription factor generally associated with a favourable outcome in T-ALL. However, the molecular mechanisms of TLX1 deregulation remain unclear and various transcript levels in the absence of 10q24 abnormalities have been reported. A reproducible and accurate delineation of TLX1+ T-ALL will be necessary for proper therapeutic stratification. We have studied 264 unselected T-ALLs (171 adults and 93 children) and show that T-ALLs expressing high levels of TLX1 (n=35, 13%), defined as a RQ-PCR ratio of TLX1>1.00E+00 ABL, form a homogeneous oncogenic group, based on their uniform stage of maturation arrest and oncogenetic and transcriptional profiles. Furthermore, TLX1-high T-ALLs harbour molecular TLX1 locus abnormalities in the vast majority (31/33), a proportion largely underestimated by standard karyotypic screening. TALLs expressing TLX1 at lower levels (n=57, 22%) do not share these characteristics. Prognostic analysis within the adult LALA94 and GRAALL03 prospective protocols demonstrate a better event-free (p=0,035) and a marked trend for longer overall survival (p=0,059) for TLX1-high T-ALLs, while the expression of lower levels of TLX1 does not impact on prognosis. We propose that TLX1+ T-ALLs be defined as cases expressing TLX1/ABL ratios >1 and/or demonstrating TLX1 rearrangement. Therapeutic modification should be considered for those patients.
Introduction:
A large proportion of T-cell Acute Lymphoblastic Leukemias (T-ALLs) show a normal (30-40%) or failed (15-20%) karyotype.
1,2 Molecular cytogenetic approaches have allowed identification an increasing number of oncogenetic lesions in this disease. 3, 4 Oncogenes such as TLX1/HOX11, TLX3/HOX11L2, TAL1 and the CALM-AF10 and MLL fusion transcripts appear lineage and stage of maturation arrest-specific and as such are likely to represent key leukemogenic features. [5] [6] [7] [8] More recently, evidence of NOTCH1 mutations in about half of T-ALLs has further enhanced the biological heterogeneity of T-ALLs. 9 However, few of these known oncogenetic markers have demonstrated clear prognostic significance. Conflicting outcomes have been associated with HOX11L2, TAL1
deregulation and NOTCH1 mutations. 7,10-14 TLX1 overexpression and/or translocation generally confers a better prognosis but this association, when found, varies between series. 11, 12, [15] [16] [17] [18] Deregulated expression of the TLX1gene, situated on chromosome 10q24, is reported in 20-
30% of T-ALLs but only 14% of adults and 4-7% of childhood T-ALLs show a 10q24
translocation when evaluated by standard karyotypic methods. 15-17-19 The stringency of the association between TLX1 expression and the presence of a translocation has therefore been questioned. 18 Observed levels of expression, assessed by Real Time Quantitative PCR (RQ-PCR), vary greatly between samples. 11, 18 The reference genes used and RQ-PCRdefined thresholds for 'high level' TLX1 expression differ between authors, which makes data comparison difficult. It has been proposed that adults with a T-ALL expressing elevated levels of TLX1 should not undergo bone marrow transplantation during first remission. 17 A stringent and standardised definition of TLX1(+) T-ALL is therefore important if it is to be used for therapeutic stratification.
We undertook this study to clarify the biological and clinical significance of TLX1 levels of expression in 264 (93 pediatric and 171 adult) T-ALLs which have undergone extensive conventional and molecular cytogenetic, immunophenotypic and oncogenetic analysis. classification, DNA and RNA extraction, immunophenotype, and TCR analysis were described previously. 5, 20, 21 cDNA synthesis was performed centrally at the Necker facility, and RNA quality assessed and normalized by quantification of ABL on an ABI PRISM 7700 or 7000 (Perkin-Elmer Applied Biosystems, Branchburg, NJ), using guidelines from the Europe Against Cancer program. 22 Samples with an ABL cycle threshold (Ct) above 32 were excluded from analysis. Each experiment included 2 nontemplate controls for contamination and all RQPCRs were performed in duplicate. All primers spanned an intron and absence of genomic amplification was confirmed by RQ-PCR from peripheral blood lymphocyte (PBL) DNA.
Transcript quantification was performed after normalization by the ABL housekeeping gene from the standard curves using the delta of delta Ct method. Primers and RQ-PCR probes have been previously reported.
8,23
Assessment of RQ-PCR amplification efficiency of TLX1 and ABL Logarithmic TLX1 plasmid dilutions were conducted and quantified by RQ-PCR. Efficiency slopes for TLX1 and ABL dilutions were comparable with respective slope values of -3,53
and -3,45. In reproducibility experiments (n=10), the Ct of detection for a dilution corresponding to one TLX1 copy per well was inconstant and varied between 38,04 and 41,1 (figure S1 on the Blood website). Hence, we considered that Cts above 38 were not quantitative and were classified as TLX1-negative.
FISH analysis
Dual color FISH experiments were performed with two sets of overlapping probes flanking the TLX1 locus on each side of the breakpoint: 5' RP11-179B2 and RP11-1031N22 labeled with FITC-dUTP and 3' RP11-324L3 and RP11-119018 labeled with Rhodamine-dUTP ( Figure S2 ). A normal TLX1 locus yields a fusion signal (Figure 2A) . A TLX1 translocation yields a split signal ( Figure 2B ).
Ligation-Mediated PCR (LM-PCR)
LM-PCR was performed using a Jδ1 or Dδ3 probe, as described. 24 Briefly, 1µg of DNA was digested with 2 blunt end restriction enzymes, DraI and PvuII. Ligation of 50pmol of an adaptor to both ends of the restriction fragments was followed by two rounds of PCR using nested adaptator-specific primers and the Jδ1 or Dδ3 specific primers respectively 5'-gTTCCACAgTCACgggTTC-3' and 5'-TgggACCCAgggTgAggATAT-3'. The LM-PCR products were sequenced in both directions using the Jδ1 primer and the nested adaptor specific primer. The sequences were blasted in the NCBI nucleotide database. 
Alleleic expression analysis:
PCR amplification and sequencing of genomic DNA identified polymorphic markers in the 3' untranslated region (3'UTR) of TLX1, as described. 25 DNAse-treated mRNA from heterozygous samples was reverse transcribed, amplified and sequenced. The mono-or biallelic expression pattern was determined by sequence analysis.
Large scale expression analysis :
An independent series of 92 T-ALL samples from Saint-Louis Hospital (Paris, France), including 56 children (median age 9 years; range 1 to 15) and 36 adults (median age 27; range 17 to 66) was previously analysed by large scale expression analysis using Preliminary results have been presented recently, with a median follow-up of 18 months. 26 We report here on 33 patients with available cDNA for our analysis. The outcome for these 33 patients did not differ from the overall 74 T-ALLs included in the GRAALL-2003.
Statistical analysis
Patient characteristics and CR rates were compared using the Fisher exact test while median comparisons were performed with the Mann-Whitney test. Overall survival (OS) was calculated from the date of randomization until the date of death or last contact. Event-free survival (EFS) was calculated from the date of randomization until the date of induction failure, first relapse, death, or last contact. OS and EFS were estimated by the Kaplan-Meier method, 27 then compared by the log-rank test. 28 For OS and EFS estimations and comparisons, all patients who received an allogeneic stem cell transplantation (SCT) were censored at SCT time. Adjustments were performed using the Cox model and tested by the log likelihood ratio test. All calculations were performed using the STATA software, version 9.0 (Stata Corporation, College Station, TX, USA).
RESULTS:
RQ-PCR TLX1 quantification defines 3 groups of T-ALL: 
>90% of TLX1-high T-ALLs have an abnormal 10q24 locus and show monoallelic

TLX1 expression:
Karyotype results were available for 175 cases (22 failed and 67 unavailable). Eleven (6%)
show clonal 10q24 abnomalities, all 11 cases belonged to the TLX1-high group. However, 17 TLX1-high T-ALLs with successful karyotypes did not demonstrate 10q24 rearrangement ( Table 1 was observed in all 12. Of note, one of the two TLX1-high samples for whom no TLX1 cytogenetic lesion was evidenced by FISH or LM-PCR was evaluable for allele-specific expression and showed a monoallelic pattern of TLX1 expression.
TLX1-low T-ALLs have an intact 10q24 locus :
Among the 42 TLX1-low T-ALLs with an available karyotype, none showed karyotypic 10q24 abnormalities (Table 1) . FISH analysis was performed for 14 TLX1-low T-ALLs.
The TLX1 locus appeared intact in all of these cases, including the 3 patients expressing the highest TLX1 levels of the TLX1-low group. FISH was also performed on 11 cell lines expressing low levels of TLX1 and all showed normal TLX1 loci. Among TLX1-high samples, the sequenced translocation breakpoints on chromosome 10, identified by LM-PCR, were relatively clustered (full details of this cluster will be published in detail elsewhere). One particular set of primers successfully amplified 30% of the TLX1-TCR junctions among the 21 TLX1-high samples tested. The sensitivity of this primer set was evaluated at 10 x 10E-3/-4 log dilution (Figure 3) . In order to verify whether we could evidence a minor TCRD-TLX1 subclone causing the low TLX1 expression in the TLX1-low T-ALLs, we searched the TLX1-low samples for TCRD-TLX1 rearrangements with this designed PCR primer set. A total of 30 TLX1-low T-ALLs were tested but no TLX1-TCRD junctions were amplified. For allele specific expression analysis, it was not possible to amplify sufficient cDNA from the 3'UTR region of a significant number of TLX1-low samples in order to reliably study their allelic expression.
TLX1-high but not TLX1-Low T-ALL share common immuno-genotypic and transcriptional features:
Of the 264 T-ALLs, 241 cases have undergone TCR expression and rearrangement analysis and have been TCR classified as described. 20 All 32 TLX1-high tested demonstrated TCRB V(D)J rearrangement on at least one allele and an uniform CD34-(31/32, 97%) CD1a+
(32/32, 100%) CD4/8 DP (28/32, 87%) cortical phenotype. They were closely correlated (90%) to an IMB/pre-AB stage of maturation arrest (Table 2) . 20 TLX1-low and TLX1-neg T-ALLs were not tightly linked to any specific stage of maturation arrest although the TLX1-low group harbours less TCR-expressing cases compared to the TLX1-neg group (p=0.01).
TLX1-high T-ALLs expressed TLX1 by definition and were uniformly negative for TLX3, CALM-AF10 or SIL-TAL1 (table 3) . In contrast, TLX1-low T-ALLs constituted a heterogeneous oncogenic subgroup. Interestingly more "HOX" expressing cases such as TLX3+ or CALM-AF10+ samples 29 were found among the TLX1-low samples (p<0.05) compared to the TLX1-negative T-ALLs.
TLX1 and array analysis of an independent series of 92 T-ALLS
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Homogeneous T-ALL oncogenic subgroups (TAL-RA, TAL-RB, MLL, CALM-AF10, HOXA-t, TLX1, TLX3, and Immature) have been defined by gene expression profiling from an independent series of 92 T-ALL samples, using unsupervised clustering (U133A Affymetrix microarray) and correlation with immunological and oncogenic transcript expression data. 8 We measured TLX1 expression levels in these cases by RQ-PCR using identical conditions and classified cases as TLX1-high, -low, and -negative cases as described above. Distribution of the cases within the oncogenic subgroups was analysed with respect to the TLX1 status. As expected, all TLX1-high cases shared a homogeneous gene expression profile and clustered in the TLX1 subgroup. In contrast, TLX1-low cases were distributed amongst the other subgroups (Figure 4 ), as were TLX1-negative cases. There were 20 TLX1-high, 37 TLX1-low and 74 TLX1-neg samples. Patient characteristics among the three subgroups are shown in Table 4 . Overall, 118/131 patients (90%) achieved CR including 20/20 patients in the TLX1-high, 30/37 in the TLX1-low and 68/74 in the TLX1-neg subgroup. However, the achievement of CR at first induction was greater in the TLX1-high subgroup as compared to combined TLX1-low and TLX1-neg subgroups (Table   4) . Median EFS of all 131 patients was 23 months. EFS events were induction death in 5 patients (3, 2, and 0 in the TLX1-neg, -low, and -high subset, respectively), resistance to induction in 8 patients (3, 5, and 0 in the TLX1-neg, -low, and -high subset, respectively), relapse in 54 patients (32, 15, and 7 in the TLX1-neg, -low, and -high subset, respectively; including 1 relapse after SCT), and death in first CR in 6 patients (3, 2, and 1 in the TLX1-neg, -low, and -high subset, respectively; including 4 deaths after SCT). After censoring at stem cell transplantation (SCT) time, median EFS of TLX1-neg, -low, and -high patients was 20 months, 16 months, and not reached, respectively ( Figure 5A , P=0.04 by log-rank test 
Discussion:
In this study, we sought to determine the onco-biological and clinical significance of TLX1 expression in T-ALL, since published data on the subject were conflicting. We show that two independent groups of TLX1-expressing T-ALLs exist: a homogenous good prognosis group with high level TLX1 expression, due to TLX1-TCR juxtapositioning in the majority, and a heterogeneous group with low level TLX1 expression and neutral prognostic impact.
Therapeutic stratification of TLX1+ T-ALL is increasingly envisaged; this will require reproducible distinction of TLX1-high and TLX1-low T-ALL within the different prospective adult and pediatric T-ALL trials.
High level expression was defined as TLX1/ABL RQ-PCR ratios greater than 1 (TLX1>1.E+00 ABL), with a clear demarcation of at least one log from TLX1-low cases.
Distinction of low level expression from TLX1 negativity depends on the sensitivity of the technique. We considered samples with an absolute TLX1 Ct higher than 38 to be TLX1-negative, based on reproducibility experiments conducted with TLX1 plasmid dilutions.
This ensured that the TLX1-low group expressed reasonably quantificable TLX1 amounts.
The fact that no TLX1 was detected in normal peripheral blood, bone marrow, thymic cDNA or genomic DNA confirms the leukemic origin of these low level TLX1 transcripts.
This bi-modal pattern of TLX1 expression in T-ALL has been reported but its biological significance was unexplored 11 . Multicenter reproducibility of these RQ-PCR criteria needs to be evaluated.
TLX1-high T-ALLs corresponded to 18% of adult and 5% of pediatric cases, in keeping with similar estimates 11, 23 , but lower than reported by other authors 17, 18 . Only 39% demonstrated karyotypic 10q24 abnormalities, despite the fact that the incidence of 10q24 abnormalities (1/56 ; 2% of pediatric and 10/119 ; 8% of adult T-ALLs) and the overall karyotype failure rate (22/197 ; 11%) approximated published prevalences 17, 18 . Combined reported here clearly show that only high levels of TLX1 expression confer a better prognosis. TLX1 translocation or expression has generally been associated with a better prognosis, although the strength of the association varies between series and small patient numbers often preclude appropriate prognostic evaluation 1, 11, 15 The absence of a standardised PCR definition of TLX1-positive T-ALLs also makes data comparison difficult. Notably, the trend towards better prognosis seems to be more pronounced when authors consider 'high' TLX1 expressors or TLX1-translocated samples. 11, 17, 18 A better leukemia-free survival in adult T-ALL was associated with high TLX1 expression in the study by Ferrando et al. 17 A trend for a better outcome was observed in pediatric T-ALL by Kees and al. 18 , when 19.7% of the cohort was classified as TLX1-high, compared to only 5% in the present series. It is possible that the use of a higher threshold to define TLX1-high T-ALL would have allowed even better prognosis discrimination, although performing such an analysis in pediatric protocols would require large patient numbers, given the relative rarity of pediatric TLX1-high T-ALL, as defined here. Since all T-ALLs with 10q24 abnormalities correspond to TLX1-high cases, the t(10;14) is associated with a trend toward better EFS even with limited patient numbers in both pediatic and adult T-ALL. Taken together, the importance of a standardized definition of TLX1 positivity can not be overstressed if, as suggested in adult T-ALL, 17 TLX1 status is to be used to dictate therapeutic decisions such as bone marrow transplantation. As detailed above, we propose that TLX1-high T-ALLs should be defined by a molecular RQ-PCR approach, refined when necessary by FISH, although initial FISH screening will detect the majority of cases and will need to be considered if RQ-PCR classification does not prove reproducible in interlaboratory comparisons within prospective clinical trials. We also propose that within adult T-ALL, TLX1 positivity be restricted to cases with 10q24 rearrangement and/or TLX1/ABL RQ-PCR ratios >1 and that such cases be stratified as low risk acute leukemia. All adult cases with lower RQ-PCR ratios and absence of 10q24 rearrangements by FISH with appropriate probes should be considered TLX1-negative. It is probable that similar criteria will be appropriate in pediatric T-ALL, but this will require assessment within prospective large scale trials. || (10)(q24) aberrations included: t(10;14)(q24;q11) in 7 cases, t(7;10)(q35;q24) in 2 cases, del(10)(q24) and der(10) for 1 case each. IM, immature; IMB, Immature with V-D-J TCRB but cTCRB negative; pre-AB, surface TCR negative, cTCRB expressing cases; TCR-AB, αβ T Cell Receptor-expressing; TCR-GD, γδ T Cell Receptor-expressing. 08 by log-rank test) ; after adjustment for trial and age, the P value for the TLX1-high vs TLX1-low/-neg comparison was 0.059.
